PROLARIS® + AI PROSTATE CANCER PROGNOSTIC TEST

Introducing the Prolaris + AI Test: A new generation of integrated prostate prognostics

The Prolaris + AI Test sets a new standard by uniting clinical-pathological features, a proven molecular score, and AI-driven digital pathology into one comprehensive prognostic test for untreated patients with localized prostate cancer.1-5


PROLARIS® + AI PROSTATE CANCER PROGNOSTIC TEST

Introducing the Prolaris + AI Test: A new generation of integrated prostate prognostics

The Prolaris + AI Test sets a new standard by uniting clinical-pathological features, a proven molecular score, and AI-driven digital pathology into one comprehensive prognostic test for untreated patients with localized prostate cancer.1-5

Prostate cancer risk assessment is evolving from traditional, standalone measures to integrated, comprehensive precision. 

Move beyond traditional, standalone measures toward approaches that bring together clinical insight, pathology, genomics, and AI to deliver a more complete understanding of disease biology — to help make complex decisions simpler and help avoid over or under treatment.   

Myriad helped define the last decade of innovation by introducing the first genomic test to measure prostate tumor aggressiveness. Today, we are shaping the next era – setting a new standard that unites clinico-pathology, genomics, and now AI driven digital pathology to bring even greater confidence to prostate cancer management decisions. 

Personalizing active surveillance (AS) protocols demands insights beyond clinical features

Many patients eligible for active surveillance may safely defer definitive treatment for at least 10 years.6 That could mean more time living life, not managing treatment and side-effects.

The Prolaris + AI Test provides critical information to help support discussions with your intermediate-risk patients that are considering active surveillance.

Until now, no single test could help inform both if a patient is safe for AS and how intensive the AS protocol should be. The Prolaris + AI Test is the first and only genomic biomarker to provide two independent metrics specifically designed for active surveillance decisions. These metrics can help support discussions with your intermediate-risk patients that are considering active surveillance based on their individual risk.

  1. Confirm active surveillance
    Is this patient appropriate for active surveillance?
    An active surveillance threshold clinically validated in untreated patients, making it uniquely suited to guide safe active surveillance selection7-9
  2. Plan personalized AS follow-up
    Is this patient likely to have a higher Gleason score at next biopsy?
    A digital-pathology AI-based metric for the likelihood of a higher Gleason score at next biopsy to help personalize AS management5

Speak with our team about how the Prolaris + AI Test can support confident decisions

Request a consultation or receive more information about integrating the Prolaris + AI Test into your clinical workflow.

Download Physician Guide



Hidden Fields










By submitting this form, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may unsubscribe from these communications by following the unsubscribe link or the instructions provided in the communication we send. The information you submit is governed by our Privacy Notice and our website Terms of Use.

Three integrated dimensions of risk. One actionable report.

Clear results. Real-world impact.​

The Prolaris Test helps inform providers on potential changes to treatment plans.

In real-world clinical studies, the Prolaris Test influenced treatment decision changes in up to 65% of cases, helping clinicians to shift between active surveillance and definitive treatment based on individual risk.10,11

In a recent study, patients recommended for active surveillance by the Prolaris Test were twice as likely to choose it and had 50% higher 3-year durability compared to those recommended for definitive treatment.9

Up to 65%

of patients tested with the Prolaris Test had a change in their treatment plan10,11

Choose the clarity that only the Prolaris + AI Test provides

  • Two clinically validated thresholds to help determine which patients should pursue treatment and which patients can appropriately choose active surveillance7,12
  • An active surveillance threshold validated in untreated patients, making it uniquely suited to guide initial treatment decisions7
  • A digital‑pathology AI-based metric for the likelihood of higher Gleason score at next biopsy to help personalize AS management5

Confirm active surveillance

Identify which patients are appropriate for active surveillance

Because the Prolaris Test is the only biomarker with an AS threshold uniquely developed and validated in untreated patients, AS conversations with the untreated patient in front of you are more relevant and informed.12

The Prolaris Test outperforms other biomarkers in selecting active surveillance candidates.13

The Prolaris Test offers long-term prognostic risk that has been extensively validated across large, diverse cohorts to consistently identify appropriate candidates for active surveillance.4,7,13

A meta-analysis of 8,478 patients demonstrates independent prognostic performance for distant metastasis and prostate cancer-specific mortality (HR 2.28; 95% CI 1.98–2.62; p=9.1×10-9).4

Active surveillance Personalization

Plan personalized AS follow-up

The Prolaris + AI Test helps confirm and personalize AS management5

Below average
Consider a less intensive AS approach:
  • Delay confirmatory biopsy
  • Less frequent biopsies
  • MRI-driven surveillance
  • Less frequent PSA testing
  • Less frequent DREs
Elevated
Consider a more intensive AS approach:
  • Early confirmatory biopsy
  • More frequent biopsies
  • Emphasis on MRI-targeted cores
  • Template or saturation biopsy
  • More frequent PSA testing
  • More frequent DREs

Using existing digitized H&E slides, the Prolaris + AI Test informs AS planning by providing a tool to help determine intensity.5

AI-powered digital pathology reveals image‑based features of aggressiveness that may not be captured by routine clinical or pathological measures to independently predict the likelihood of higher Gleason score at next biopsy.5

In a validation study (N=296), the AI metric was a significant independent predictor of upgrade (OR 1.60 per SD; p=0.0003), while time‑to‑biopsy is not significant.5

Single-modal Treatment

Identify the patients who need definitive treatment and at what intensity

The Prolaris Test shows that those patients who fall below the multi-modal threshold do not benefit from intensifying treatment14

Establishing the multi-modal threshold

The Prolaris Test threshold was developed on approximately 1,500 intermediate and high-risk patients from two separate cohorts.

Validating patients prior to a multi-modal treatment

Patients were separated by those who received single-modal therapy versus those with multiple modes of treatment.

Multi-modal Threshold

Guide the androgen deprivation therapy (ADT) conversation

Multiple groups with ADT variations evaluated for metastasis

The Multi-modal threshold was developed and double-validated across all outcomes to predict the risk of metastasis and determine which patients can appropriately forego ADT.14,15

At or below the multi-modal threshold
(8.8% metastasis risk)

The Prolaris Test gives your patients personalized, shareable guidance and a simple “number-needed-to-treat” value.

Is ADT right for this patient?

Faster results.
Smarter workflow.​

Myriad Oncology™ helps customize your ordering process to meet your practice’s unique needs. With a physician-driven, conditional ordering model, Prolaris + AI testing can be initiated directly from the pathology lab — so you get critical results faster, right when treatment decisions are being made.​

The beauty of conditional ordering? You stay in control — you decide which patients to test, and Myriad builds a workflow to support that​.

Access detailed ordering instructions, specimen handling guidelines, and pathology resources to streamline every step of the testing process.

Graphic showing why to streamline your process from basic ordering to streamlined ordering

Understanding the Prolaris + AI Test Report

Imagine having a tool to clearly explain risks, thresholds, and treatment implications to your patients, step-by-step. The Prolaris + AI Test results are designed with patients and providers in mind to quickly answer pressing clinical questions, improving confidence in selecting the most appropriate management option.

AI brings a new level of precision to managing AS in prostate cancer 

  • AI addresses potential diagnostic blind spots in newly diagnosed patients 
  • Patients may face uncertainty due to sampling errors, missed grading, and interobserver variability.  
  • AI may reveal what traditional tools miss 
  • AI-powered digital pathology detects subtle morphometric patterns indicative of cancer aggressiveness in biopsy tissue that may be imperceptible to the human eye. 
  • AI complements genomics for a more complete picture 

AI doesn’t replace genomic testing; it enhances it. When combined with the Prolaris Test, AI adds independent, image-based insights that strengthen risk stratification. This comprehensive approach is uniquely developed and validated in untreated patients.5 

Santa golfing

More resources

Additional resources

0

Myriad Oncology for urologists

Explore more tests and resources to support your prostate cancer patients.

0

Modern Urologist Podcast

This casual, yet educational, podcast is committed to keeping you informed on all things urology.

0

Provider Stories

Hear from fellow clinicians on how the Prolaris+AI Test has changed the way they manage prostate cancer care.

This page includes AI generated images. Any similarity or resemblance to persons, living or dead, is purely coincidental.

References:

  1. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245-255
  2. Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106(6):1095-1099.
  3. Cuzick J, Stone S, Fisher G, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer. 2015;113(3):382-389.
  4. Morgan TM, et al. Clin Genitourin Cancer. 2026 May 20:102586. doi: 10.1016/j.clgc.2026.102586
  5. Mabey B, et al. Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance. Future Oncol. 2026 Jun 16:1-9. doi: 10.1080/14796694.2026.2686438
  6. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patient with prostate cancer. J Clinc Oncol. 2015;33(3):272-277.
  7. Lin DW, Crawford ED, Keane T, et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol Oncol. 2018;36(6):310.e7-310.e13.
  8. Kaul S, Wojno KJ, Stone S, et al.Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. Per Med. 2019;16(6):491-499.
  9. Lenz L, Clegg W, Iliev D, et al. Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing. Prostate Cancer Prostatic Dis. 2025;28(2):427-434.
  10. Shore ND, Kella N, Moran B, et al. Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. J Urol. 2016;195(3):612-618.
  11. Crawford ED, Scholz MC, Kar AJ, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014;30(6):1025-1031.
  12. Tward JD, Schlomm T, Bardot S, et al. Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. Clin Genitourin Cancer. 2021;19(4):296-304.e3.
  13. Hu JC, Tosoian JJ, Qi J, et al. Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. JCO Precis Oncol. 2018;2:PO.18.00163.
  14. Tward J, Lenz L, Flake DD II, et al. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. Int J Radiat Oncol Biol Phys. 2022;113(1):66-76.
  15. Tward JD, Schlomm T, Bardot S, et al. Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer. J Clin Oncol. 2020;38(6_suppl):346-346.

©2026 Myriad Genetics, Inc. Myriad Genetics, Myriad Oncology, Prolaris, MyRisk, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.